Skin Reactions to Hepatitis B Treatment: What You Need to Know
"Understanding interferon-induced vasculitis and how to manage skin complications during hepatitis B therapy."
Interferons (IFNs) are a group of proteins crucial for immune response, fighting viruses, and regulating cell growth. They're used to treat various conditions, including hepatitis B. However, IFN therapy can cause side effects, including skin reactions. While most reactions are mild, some can be severe, like local leukocytoclastic vasculitis (LCV) at the injection site.
Cutaneous reactions from IFN treatment can be localized or widespread. Localized reactions at the injection site typically appear as red, itchy patches. In rare cases, a more severe reaction called leukocytoclastic vasculitis (LCV) can occur, leading to skin necrosis (tissue death).
This article explores a rare case of interferon-gamma-induced LCV in a patient with hepatitis B. We'll discuss the symptoms, diagnosis, treatment, and how to minimize such complications. This information is crucial for anyone undergoing IFN therapy and healthcare providers administering it.
Skin Reactions and Treatment Impact
Cutaneous reactions associated with interferon treatment may be localized or generalized, according to a report on interferon-related skin reactions. Interferon therapy is described as an effective treatment option for chronic hepatitis B (CHB), but its outcomes are uncertain. Conventional interferon-α has been approved for CHB, and short-term studies have characterized interferon-based therapy as moderately effective. Interferon-based treatment also plays a role in pursuing sustained virological response and immune-mediated viral clearance.
Interferon’s Antiviral Foundations
Interferons are cytokines with antiviral activity, as well as immunoregulatory and antitumor effects, and they contribute to innate and adaptive immune responses. Interferon-α and its pegylated form have been used to treat chronic hepatitis B for many years. One source notes that interferons earned their name in the 1950s because they “interfere” with viral replication. More recent discussion highlights interferon-α’s ability to restrict hepatitis B virus replication and coordinate immune responses, while chronic infection remains difficult to cure in part because covalently closed circular DNA (cccDNA) persists and host immunity is impaired.
Understanding Leukocytoclastic Vasculitis (LCV)
A 19-year-old man with hepatitis B developed painful erythema and necrosis at the interferon-gamma injection site after six months of treatment. The patient had been receiving recombinant IFN-γ (6.0 × 107 units) subcutaneously every other day to decrease viral DNA. Repeating injections near the lesion worsened the pain, erythema, and necrosis.
- Angiocentric segmental inflammation
- Endothelial cell swelling
- Cellular infiltrate composed of neutrophils
- Fragmentation of nuclei
Research on Interferon Effects and Limitations
A July 2025 study used nontargeted metabolomics to investigate how pegylated interferon alfa (pegIFN-α) affects metabolites in chronic hepatitis B (CHB). Its authors describe pegIFN-α as a main CHB treatment strategy while noting significant side effects and that many patients do not respond. A March 2026 review identifies side effects, resistance, and treatment failure as challenges for interferon therapy. It points to combination therapies and improvements in interferon formulations as future research directions.
Injection-Site Reactions Are Usually Local
Local skin reactions can occasionally occur at an interferon injection site. The cited report says skin necrosis at the injection site is not frequent. This indicates that local reactions are possible, but necrosis is described as uncommon in the report.
Comparing Peginterferon and Oral Antivirals
Peginterferon and nucleos(t)ide analogues each have advantages and limitations in chronic hepatitis B, and newer, more potent treatments have changed the treatment landscape. A 2025 comparison of pegylated interferon-alpha alone and combinations with entecavir or tenofovir disoproxil fumarate (TDF) reports that TDF provides better viral suppression but also comes with more side effects. Whether interferon-α is better than nucleos(t)ide analogues for preventing adverse outcomes, including hepatocellular carcinoma, remains uncertain or controversial according to a comparative study.
Managing and Preventing LCV During Interferon Therapy
Cutaneous necrosis is a rare but severe local side effect of IFN treatment. Previous reports suggest discontinuing IFN therapy to resolve LCV lesions. Other treatments include topical care, surgical debridement, and modification of injection sites.
Emerging Research Priorities
A September 2025 study examined global research trends, collaborative networks, and emerging priorities in interferon therapy for chronic hepatitis B (CHB). It describes interferon-based therapy as playing a role in achieving sustained virological response and immune-mediated viral clearance. The study used a comprehensive literature search to analyze the research landscape. Its focus on emerging priorities points to continued investigation of interferon therapy for CHB.
Treatment Burden and Functional-Cure Potential
An April 2026 review describes pegylated interferon-α (PegIFN-α) as an immunomodulatory treatment with the potential to achieve a functional cure for chronic hepatitis B (CHB). It reports that frequent multisystem adverse reactions can constrain clinical use and lead to dose modifications or treatment discontinuation. A November 2025 chapter likewise describes Peg-IFN as an important CHB treatment expected to achieve functional cure. Together, these sources frame potential treatment benefit alongside adverse effects that can complicate continued therapy.
This case demonstrates the potential benefit of systemic corticosteroids and colchicine in managing IFN-induced LCV, without necessarily discontinuing IFN therapy. Changing the injection site is also crucial to prevent recurrence.
Patients undergoing IFN therapy should be educated about potential skin reactions and the importance of varying injection sites. Early recognition and management of LCV can prevent severe complications and improve treatment outcomes.